These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 16409202

  • 21. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels.
    Diamanti-Kandarakis E, Palioniko G, Alexandraki K, Bergiele A, Koutsouba T, Bartzis M.
    Eur J Endocrinol; 2004 Jun; 150(6):793-8. PubMed ID: 15191349
    [Abstract] [Full Text] [Related]

  • 22. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism.
    Stegnar M, Uhrin P, Peternel P, Mavri A, Salobir-Pajnic B, Stare J, Binder BR.
    Thromb Haemost; 1998 May; 79(5):975-9. PubMed ID: 9609232
    [Abstract] [Full Text] [Related]

  • 23. 4G/5G promoter polymorphism of plasminogen activator inhibitor-1, lipid profiles, and ischemic stroke.
    Chen CH, Eng HL, Chang CJ, Tsai TT, Lai ML, Chen HY, Liu CJ, Lin TM.
    J Lab Clin Med; 2003 Aug; 142(2):100-5. PubMed ID: 12960956
    [Abstract] [Full Text] [Related]

  • 24. Clinicopathological significance of plasminogen activator inhibitor-1 promoter 4G/5G polymorphism in breast cancer: a meta-analysis.
    Lee JH, Kim Y, Choi JW, Kim YS.
    Arch Med Res; 2013 Jan; 44(1):39-45. PubMed ID: 23291383
    [Abstract] [Full Text] [Related]

  • 25. Binding of upstream stimulatory factor 1 to the E-box regulates the 4G/5G polymorphism-dependent plasminogen activator inhibitor 1 expression in mast cells.
    Ma Z, Jhun B, Jung SY, Oh CK.
    J Allergy Clin Immunol; 2008 Apr; 121(4):1006-1012.e2. PubMed ID: 18234320
    [Abstract] [Full Text] [Related]

  • 26. The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes.
    Iwai N, Shimoike H, Nakamura Y, Tamaki S, Kinoshita M.
    Atherosclerosis; 1998 Jan; 136(1):109-14. PubMed ID: 9544737
    [Abstract] [Full Text] [Related]

  • 27. No association of the plasminogen activator inhibitor-1 promoter 4G/5G polymorphism with inhibitor level during basal transcription in vitro.
    Zhan M, Zhou Y, Han ZC.
    Int J Hematol; 2004 May; 79(4):400-4. PubMed ID: 15218974
    [Abstract] [Full Text] [Related]

  • 28. Tissue plasminogen activator and plasminogen activator inhibitor type 1 gene polymorphism in patients with gastric ulcer complicated with bleeding.
    Kim HS, Hwang KY, Chung IK, Park SH, Lee MH, Kim SJ, Hong SY.
    J Korean Med Sci; 2003 Feb; 18(1):58-64. PubMed ID: 12589088
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Role of functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity, and outcome of meningococcal disease in Caucasian children.
    Haralambous E, Hibberd ML, Hermans PW, Ninis N, Nadel S, Levin M.
    Crit Care Med; 2003 Dec; 31(12):2788-93. PubMed ID: 14668616
    [Abstract] [Full Text] [Related]

  • 31. The plasminogen activator inhibitor 1 4G/5G polymorphism is not associated with longevity: a study in octogenarians.
    Lottermoser K, Düsing R, Ervens P, Koch B, Brüning T, Sachinidis A, Vetter H, Ko Y.
    J Mol Med (Berl); 2001 Jun; 79(5-6):289-93. PubMed ID: 11485022
    [Abstract] [Full Text] [Related]

  • 32. Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes.
    Nagi DK, McCormack LJ, Mohamed-Ali V, Yudkin JS, Knowler WC, Grant PJ.
    Diabetes Care; 1997 Aug; 20(8):1304-9. PubMed ID: 9250459
    [Abstract] [Full Text] [Related]

  • 33. Plasminogen activator inhibitor 1 4G/5G and -844G/A variants in idiopathic recurrent pregnancy loss.
    Magdoud K, Herbepin VG, Touraine R, Almawi WY, Mahjoub T.
    Am J Reprod Immunol; 2013 Sep; 70(3):246-52. PubMed ID: 23521508
    [Abstract] [Full Text] [Related]

  • 34. Association of PAI-1 gene promoter 4g/5g polymorphism with plasma PAI-1 activity in Chinese patients with and without hypertension.
    Jeng JR.
    Am J Hypertens; 2003 Apr; 16(4):290-6. PubMed ID: 12670745
    [Abstract] [Full Text] [Related]

  • 35. [Plasminogen activator inhibitor type 1 gene polymorphism and thromboses in patients with antiphospholipid syndrome].
    Reshetniak TM, Ostriakova EV, Patrusheva NL, Patrushev LI, Aleksandrova EN, Seredavkina NV, Volkov AV, Nasonov EL.
    Ter Arkh; 2013 Apr; 85(1):76-84. PubMed ID: 23536951
    [Abstract] [Full Text] [Related]

  • 36. The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with HELLP syndrome.
    Muetze S, Eggermann T, Leeners B, Birke C, Kuse S, Ortlepp JR, Rudnik-Schoeneborn S, Zerres K, Rath W.
    J Thromb Thrombolysis; 2009 Feb; 27(2):141-5. PubMed ID: 18058192
    [Abstract] [Full Text] [Related]

  • 37. Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer.
    Eroglu A, Ulu A, Cam R, Akar N.
    J BUON; 2006 Feb; 11(4):481-4. PubMed ID: 17309181
    [Abstract] [Full Text] [Related]

  • 38. Plasminogen activator inhibitor I 4G/5G polymorphism in neonatal respiratory distress syndrome.
    Armangil D, Yurdakök M, Okur H, Gürgey A.
    Clin Appl Thromb Hemost; 2011 Aug; 17(4):352-7. PubMed ID: 20460339
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The Association of Plasminogen Activator Inhibitor Type 1 (PAI-1) Level and PAI-1 4G/5G Gene Polymorphism with the Formation and the Grade of Endometrial Cancer.
    Yıldırım ME, Karakuş S, Kurtulgan HK, Kılıçgün H, Erşan S, Bakır S.
    Biochem Genet; 2017 Aug; 55(4):314-321. PubMed ID: 28303356
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.